In the years between a warning and a withdrawal, dozens of patients in Britain received a mechanical heart device that NHS data had already marked as far more lethal than its alternative. Two of the country's leading transplant centres — Freeman Hospital in Newcastle and Harefield Hospital in London — continued implanting the Medtronic pump until the manufacturer pulled it from the market in 2021, three years after internal mortality figures had begun to speak plainly. The story of Greg Marshall, a 26-year-old who suffered a stroke, a device failure, and finally cardiac arrest, gives human wei
Daily Mail Online
· Nov 13, 2025
· health
· 3 min read
High
Sourcing: Verified
NHS hospitals continued using heart device with 2.5x higher death rate despite safety concerns
Greg Marshall, a 26-year-old patient, suffered a stroke from the device, experienced device failure, and died unexpectedly in cardiac arrest in 2023; dozens of other patients died at elevated rates.
◉
Health & Medicine
8180 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
CBS News · Aug 21
Nashville hospital drug mix-up leaves 4 patients with severe complications
Four patients at a Nashville hospital received potassium instead of pain medication during routine joint replacement sur…
BBC News · Aug 21 UK warns vulnerable groups to avoid runny eggs amid salmonella outbreakUK health authorities warn vulnerable populations to avoid undercooked eggs at restaurants due to a rapidly expanding sa…
BBC News · Aug 21 Meghan in talks for Netflix's The Gentlemen as she considers return to actingMeghan is in early talks to return to acting with a role in Netflix's The Gentlemen, marking her first significant actin…
The Pharmaceutical Journal · Aug 21 Survey reveals aesthetic goals driving weight-loss medication use over health concernsA UK survey shows 78% of respondents would consider weight-loss medications for weddings and holidays rather than health…
Bias & Framing
⚖
Article uses dramatic framing and selective evidence to portray NHS/hospitals as negligent, emphasizing patient harm while underexploring systemic complexity and decision-making rationale.
Bias Direction
center-right
Confidence
HIGH
Institutional failure narrative with emotional case study anchoring. Opens with accusatory framing ('put patients at risk'), emphasizes timeline of ignored warnings, and uses individual tragedy to personalize systemic critique. Presents binary choice (Medtronic vs. Abbott) without exploring clinical context.
put patients at risk
feared to be linked
despite this
terrified of having another stroke
refused another surgery
emerged
Statements from Freeman Hospital or Harefield Hospital explaining their clinical decision-making
Perspective from Medtronic on the timeline and safety data available to them
Expert cardiologist commentary on why the device may have remained in use (e.g., patient selection criteria, individual case factors)
Context on consultant relationships and whether they influenced decisions or were incidental
Discussion of why 2019 audit data didn't immediately trigger withdrawal
Regulatory/NHS approval process explanation
Geopolitical Impact
🌎
UK NHS hospitals continued using a Medtronic heart device with 2.5x higher mortality rates despite 2018 safety concerns, raising questions about medical device governance and corporate influence in healthcare decisions.
Escalation Risk
low
Confidence
HIGH
United Kingdom
Europe (regulatory implications)
This reflects institutional power imbalances: corporate interests (Medtronic) maintained influence through consultant relationships with hospital leadership, while regulatory oversight (NHS) lacked enforcement mechanisms to compel device discontinuation despite safety data. Reveals tension between manufacturer interests and patient safety priorities.
Similar to the PIP breast implant scandal (2010-2012) where defective medical devices remained in use despite known risks due to regulatory gaps and manufacturer influence, highlighting recurring failures in medical device oversight across healthcare systems.
Economic Lens
📈
NHS hospitals continued using a Medtronic heart device with 2.5x higher mortality rates despite 2018 safety concerns, raising questions about medical device regulation, manufacturer conflicts of interest, and healthcare accountability.
Market Signal
bearish
Confidence
HIGH
Healthcare/Medical Devices
Pharmaceuticals & Medical Equipment Manufacturing
Insurance (Health/Medical Liability)
Regulatory & Compliance Services
Patients face increased mortality risk from medical devices; reduced trust in NHS device selection processes; potential for higher insurance costs and litigation; patients may demand second opinions and alternative treatments, increasing healthcare costs.
Likely regulatory tightening of medical device approval and monitoring processes; potential mandatory independent safety reviews; stricter conflict-of-interest rules for consultant relationships between hospitals and manufacturers; possible compensation schemes for affected patients; enhanced post-market surveillance requirements.